AOBiome Therapeutics is a late stage therapeutics company addressing a broad range of inflammatory skin conditions by harnessing a single strain of Ammonia Oxidizing Bacteria (AOB), a critical part of the nitrogen cycle and by extension the immune system, whose presence as part of the human microbiome has been eliminated through modern living.

RESTORING IMMUNE FUNCTIONALITY

Ammonia Oxidizing Bacteria is involved in moderating immune response through the down-regulation of IL-4, IL-5, IL-13 and IL-31. Currently such inflammatory markers are targeted individually by on-market compounds and biologics. However, B244 targets those pathways simultaneously as ammonia oxidizing bacteria works as an extension of the immune system as opposed to a one off targeter of only certain cytokines. Such markers are associated with inappropriate inflammatory response in several diseases including atopic dermatitis and pruritus (itch) which is the basis for the science of our drug development program. In addition, these bacteria provide other benefits that include the production of skin metabolites which are pervasive throughout the cosmetic industry to help balance moisture and skin barrier functions, as well as down regulating bacterial populations that can lead to infections and other skin dysbiosis.